These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 28376157

  • 1. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 2. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376184
    [Abstract] [Full Text] [Related]

  • 3. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.
    BMC Cancer; 2013 Sep 03; 13():404. PubMed ID: 24007603
    [Abstract] [Full Text] [Related]

  • 4. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone.
    Haab B, Qian L, Staal B, Jain M, Fahrmann J, Worthington C, Prosser D, Velokokhatnaya L, Lopez C, Tang R, Hurd MW, Natarajan G, Kumar S, Smith L, Hanash S, Batra SK, Maitra A, Lokshin A, Huang Y, Brand RE.
    Cancer Lett; 2024 Nov 01; 604():217245. PubMed ID: 39276915
    [Abstract] [Full Text] [Related]

  • 5. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S.
    Cancer Prev Res (Phila); 2021 Jul 01; 14(7):729-740. PubMed ID: 33893071
    [Abstract] [Full Text] [Related]

  • 6. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
    Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, Fabianova E, Holcatova I, Janout V, Feng Z, Yip-Schneider M, Zhang J, Brand R, Taguchi A, Maitra A, Brennan P, Max Schmidt C, Hanash S.
    J Natl Cancer Inst; 2019 Apr 01; 111(4):372-379. PubMed ID: 30137376
    [Abstract] [Full Text] [Related]

  • 7. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L.
    Cancer Sci; 2018 Sep 01; 109(9):2841-2851. PubMed ID: 29945294
    [Abstract] [Full Text] [Related]

  • 8. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
    Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM.
    Clin Cancer Res; 2014 Nov 15; 20(22):5787-95. PubMed ID: 25239611
    [Abstract] [Full Text] [Related]

  • 9. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z.
    Cancer Epidemiol Biomarkers Prev; 2019 Jan 15; 28(1):174-182. PubMed ID: 30333219
    [Abstract] [Full Text] [Related]

  • 10. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.
    Pancreas; 2013 Mar 15; 42(2):193-7. PubMed ID: 23407481
    [Abstract] [Full Text] [Related]

  • 11. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W.
    Int J Cancer; 2021 Apr 15; 148(8):2048-2058. PubMed ID: 33411965
    [Abstract] [Full Text] [Related]

  • 12. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S, Taylor WR, Foote PH, Berger CK, Wu CW, Mahoney DW, Bamlet WR, Burger KN, Postier N, de la Fuente J, Doering KA, Lidgard GP, Allawi HT, Petersen GM, Chari ST, Ahlquist DA, Kisiel JB.
    Clin Cancer Res; 2021 May 01; 27(9):2523-2532. PubMed ID: 33593879
    [Abstract] [Full Text] [Related]

  • 13. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB.
    Clin Cancer Res; 2019 May 01; 25(9):2745-2754. PubMed ID: 30617132
    [Abstract] [Full Text] [Related]

  • 14. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS.
    Sci Transl Med; 2017 Jul 12; 9(398):. PubMed ID: 28701476
    [Abstract] [Full Text] [Related]

  • 15. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.
    Clin Cancer Res; 2006 Jan 15; 12(2):442-6. PubMed ID: 16428484
    [Abstract] [Full Text] [Related]

  • 16. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
    Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E.
    Br J Cancer; 2013 May 14; 108(9):1846-53. PubMed ID: 23579209
    [Abstract] [Full Text] [Related]

  • 17. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec 14; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 18. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T.
    PLoS One; 2016 Dec 14; 11(8):e0161009. PubMed ID: 27579675
    [Abstract] [Full Text] [Related]

  • 19. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT, Brünner N, De Muckadell OB.
    Anticancer Res; 2010 Feb 14; 30(2):587-92. PubMed ID: 20332475
    [Abstract] [Full Text] [Related]

  • 20. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, Qian L, Zhao J, Zong H, Kang B, Zou WB, Chen K, He X, Meng Z, Chen Z, Huang S, Wang P.
    Gut; 2020 Mar 14; 69(3):540-550. PubMed ID: 31562239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.